| 10.38 -0.21 (-1.98%) | 10-01 00:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Hancock Jaffe Laboratories, Inc. is a medical device company in its developmental stage, specializing in creating advanced tissue-based and biologic solutions. These innovations are engineered to either sustain or significantly enhance the lives of patients afflicted with cardiovascular, peripheral arterial, and venous diseases, as well as end-stage renal disease (ESRD). The firm, headquartered in Irvine, California, maintains a dedicated team of nine full-time employees. Among its key initiatives, the company is actively developing implantable bioprosthetic devices for cardiovascular applications. This includes the Bioprosthetic Heart Valve (BHV), a swine-derived heart valve designed to mimic the function of a native heart valve and provide superior performance compared to current prosthetic options. Furthermore, the company is developing a Venous Valve, another bioprosthetic device sourced from pig tissue. This valve is specifically designed for individuals suffering from chronic venous insufficiency (CVI) in the lower limbs, a condition frequently resulting from damage to leg vein valves after the formation of deep venous blood clots.
Thu, 20 Feb 2025
Hancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDA - ACCESS Newswire
Sun, 03 Oct 2021
enVVeno Medical (Nasdaq:NVNO) - Stock Analysis - Simply Wall Street
Tue, 25 Aug 2020
4 Penny Stocks To Buy According To Analysts; 1 Up 100% This Month - PennyStocks.com
Wed, 09 Jan 2019
Hancock Jaffe sets endpoints for FIH VenoValve study - MassDevice
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|